Targeting epstein-barr virus-associated lymphomas

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 830-832

  Nikiforow, Sarah ^a   LaCasce, Ann S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 3C; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; UNCLASSIFIED DRUG; VIRUS PROTEIN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

ARTICLE; B LYMPHOCYTE ACTIVATION; BURKITT LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HODGKIN DISEASE; HUMAN; IMMUNOBLASTIC LYMPHOMA; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEMORY CELL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; VIRUS REPLICATION; ADOPTIVE IMMUNOTHERAPY; FEMALE; GENE THERAPY; IMMUNOLOGY; MALE; METHODOLOGY; NOTE; TRANSPLANTATION;

FEMALE; GENETIC THERAPY; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA; MALE; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 84899627081     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.2994     Document Type: Article

References (32)

1. Burkitt D: A children's cancer dependent on climatic factors. Nature 194:232-234, 1962
2. Miller G, Lisco H, Kohn HI, et al: Establishment of cell lines from normal adult human blood leukocytes by exposure to Epstein-Barr virus and neutralization by human sera with Epstein-Barr virus antibody. Proc Soc Exp Biol Med 137:1459-1465, 1971
3. Murray RJ, Kurilla MG, Brooks JM, et al: Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176:157-168, 1992
4. Miyashita EM, Yang B, Babcock GJ, et al: Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 71:4882-4891, 1997 (Pubitemid 27258155)
5. Rooney CM, Smith CA, Ng CY, et al: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549-1555, 1998 (Pubitemid 28406858)
6. Haque T, Wilkie GM, Taylor C, et al: Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360:436-442, 2002 (Pubitemid 34880139)
7. Barker JN, Doubrovina E, Sauter C, et al: Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 116:5045-5049, 2010
8. Bollard CM, Gottschalk S, Torrano V, et al: Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol [epub ahead of print on December 16, 2013]
9. Babcock GJ, Hochberg D, Thorley-Lawson AD: The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497-506, 2000
10. Hochberg D, Middeldorp JM, Catalina M, et al: Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 101:239-244, 2004 (Pubitemid 38084234)
11. Zhao B, Zou J, Wang H, et al: Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A 108:14902-14907, 2011
12. Thorley-Lawson DA, Gross A: Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328-1337, 2004 (Pubitemid 38375368)
13. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757-768, 2004 (Pubitemid 39331148)
14. Zimber-Strobl U, Strobl LJ: EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin Cancer Biol 11:423-434, 2001 (Pubitemid 33105021)
15. Hatzivassiliou EG, Kieff E, Mosialos G: Constitutive CD40 signaling phenocopies the transforming function of the Epstein-Barr virus oncoprotein LMP1 in vitro. Leuk Res 31:315-320, 2006 (Pubitemid 46073180)
16. Leen A, Meij P, Redchenko I, et al: Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 75:8649-8659, 2001 (Pubitemid 32768969)
17. Miller CL, Burkhardt AL, Lee JH, et al: Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155-166, 1995
18. Caldwell RG, Wilson JB, Anderson SJ, et al: Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405-411, 1998 (Pubitemid 28462761)
19. Ning RJ, Xu XQ, Chan KH, et al: Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins. Immunology 134:161-171, 2011
20. Chen F, Zou JZ, di Renzo L, et al: A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 69:3752-3758, 1995
21. Yates JL, Warren N, Sugden B: Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313:812-815, 1985 (Pubitemid 15130835)
22. Catalina MD, Sullivan JL, Bak KR, et al: Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol 167:4450-4457, 2001 (Pubitemid 32954322)
23. Blake N, Haigh T, Shaka'a G, et al: The importance of exogenous antigen in priming the human CD8+ T cell response: Lessons from the EBV nuclear antigen EBNA1. J Immunol 165:7078-7087, 2000 (Pubitemid 32001182)
24. Heslop HE, Slobod KS, Pule MA, et al: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935, 2009
25. Rooney CM, Roskrow MA, Suzuki N, et al: Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol 9:S129-S132, 1998 (Pubitemid 29049132)
26. Bollard CM, Aguilar L, Straathof KC, et al: Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's Disease. J Exp Med 200:1623-1633, 2004 (Pubitemid 40094186)
27. Hasan AN, Kollen WJ, Trivedi D, et al: A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. J Immunol 183:2837-2850, 2009
28. Icheva V, Kayser S, Wolff D, et al: Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31:39-48, 2013
29. Gottschalk S, Edwards OL, Sili U, et al: Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101:1905-1912, 2003 (Pubitemid 36237592)
30. Nikiforow S, Bottomly K, Miller G, et al: Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 77:12088-12104, 2003 (Pubitemid 37339862)
31. Heller KN, Upshaw J, Seyoum B, et al: Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 109:1138-1146, 2007 (Pubitemid 46220661)
32. Gerdemann U, Katari UL, Papadopoulou A, et al: Safety and clinical efficacy of rapidly generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem-cell transplant. Mol Ther 21:2113-2121, 2013